Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03834506 |
Recruitment Status :
Recruiting
First Posted : February 8, 2019
Last Update Posted : February 24, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The purpose of this study is to assess the efficacy and safety of the combination of pembrolizumab (MK-3475) and docetaxel in the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) who have not received chemotherapy for mCRPC but have progressed on or are intolerant to Next Generation Hormonal Agent (NHA).
There are two primary study hypotheses.
Hypothesis 1: The combination of pembrolizumab plus docetaxel plus prednisone is superior to placebo plus docetaxel plus prednisone with respect to Overall Survival (OS).
Hypothesis 2: The combination of pembrolizumab plus docetaxel plus prednisone is superior to placebo plus docetaxel plus prednisone with respect to Radiographic Progression-free Survival (rPFS) per Prostate Cancer Working Group (PCWG)-modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by blinded independent central review.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Prostatic Neoplasms | Biological: Pembrolizumab Drug: Docetaxel Drug: Prednisone Drug: Placebo Drug: Dexamethasone | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 1000 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) Plus Docetaxel Plus Prednisone Versus Placebo Plus Docetaxel Plus Prednisone in Participants With Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Progressed on a Next Generation Hormonal Agent (NHA) (KEYNOTE-921) |
Actual Study Start Date : | May 2, 2019 |
Estimated Primary Completion Date : | September 12, 2021 |
Estimated Study Completion Date : | February 28, 2023 |

Arm | Intervention/treatment |
---|---|
Experimental: Pembrolizumab+Docetaxel
On Day 1 of each 21-day cycle, participants receive dexamethasone 8 mg by oral tablets at 12 hours, 3 hours and 1 hour prior to docetaxel administration PLUS docetaxel 75 mg/m^2 by intravenous (IV) infusion for up to a maximum of 10 cycles (approximately 7 months). Participants receive prednisone 5 mg by oral tablets twice daily during each docetaxel cycle up to a maximum of 10 cycles (approximately 7 months). Participants also receive pembrolizumab 200 mg by IV infusion on day 1 of each 21-day cycle for up to a maximum of 35 cycles (approximately 2 years).
|
Biological: Pembrolizumab
IV infusion
Other Names:
Drug: Docetaxel IV infusion
Other Name: TAXOTERE® Drug: Prednisone Oral tablets Drug: Dexamethasone Oral tablets
Other Name: DECADRON® |
Placebo Comparator: Placebo+Docetaxel
On Day 1 of each 21-day cycle, participants receive dexamethasone 8 mg by oral tablets at 12 hours, 3 hours and 1 hour prior to docetaxel administration PLUS docetaxel 75 mg/m^2 by IV infusion for up to a maximum of 10 cycles (approximately 7 months). Participants receive prednisone 5 mg by oral tablets twice daily during each docetaxel cycle up to a maximum of 10 cycles (approximately 7 months). Participants also receive placebo by IV infusion on day 1 of each 21-day cycle for up to a maximum of 35 cycles (approximately 2 years). |
Drug: Docetaxel
IV infusion
Other Name: TAXOTERE® Drug: Prednisone Oral tablets Drug: Placebo IV infusion
Other Name: Normal saline or dextrose infusion Drug: Dexamethasone Oral tablets
Other Name: DECADRON® |
- Overall Survival (OS) [ Time Frame: Up to approximately 28 months ]Time from randomization to death due to any cause
- Radiographic Progression-free Survival (rPFS) Per Prostate Cancer Working Group (PCWG)-modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review [ Time Frame: Up to approximately 28 months ]Time from randomization to radiographic progression, or death due to any cause, whichever occurs first
- Time to Initiation of the First Subsequent Anti-cancer Therapy (TFST) [ Time Frame: Up to approximately 28 months ]Time from randomization to initiation of the first subsequent anti-cancer therapy or death, whichever occurs first
- Prostate-specific Antigen (PSA) Response Rate [ Time Frame: Up to approximately 28 months ]Percentage of participants in the analysis population who have a negative change (decrease) in PSA level of ≥50% measured twice ≥3 weeks apart
- Objective Response Rate (ORR) Per Prostate Cancer Working Group (PCWG)-modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review [ Time Frame: Up to approximately 28 months ]Percentage of participants in the analysis population who have a best overall response of either confirmed Complete Response (CR) or a confirmed Partial Response (PR) per PCWG-modified RECIST 1.1
- Duration of Response (DOR) Per Prostate Cancer Working Group (PCWG)-modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review [ Time Frame: Up to approximately 28 months ]Time from first documented evidence of confirmed Complete Response (CR) or Partial Response (PR) per PCWG-modified RECIST 1.1 until disease progression or death from any cause, whichever occurs first
- Time to Pain Progression (TTPP) as Assessed by Brief Pain Inventory-Short Form (BPI-SF) Item 3 ("Worst Pain in 24 Hours") and Opiate Analgesic Use (Analgesic Quantification Algorithm [AQA] Score) [ Time Frame: Up to approximately 28 months ]Time from randomization to pain progression. In this study, pain progression will be assessed by participant responses to Item 3 of the BPI-SF and participant AQA Scores which are both assessed by participants daily for 7 consecutive days
- Time to First Symptomatic Skeletal-related Event (SSRE) [ Time Frame: Up to approximately 28 months ]Time from randomization to the first SSRE. SSRE is defined as radiation to prevent or relieve skeletal symptoms, occurrence of new symptomatic pathological fracture, spinal cord compression, or surgery to bone
- Time to Prostate-specific Antigen (PSA) Progression [ Time Frame: Up to approximately 28 months ]Time from randomization to PSA progression. PSA progression date is defined as the date of 1) ≥25% increase and ≥2 ng/mL above the nadir, confirmed by a second value ≥3 weeks later if there is PSA decline from baseline, or 2) ≥25% increase and ≥2 ng/mL increase from baseline beyond 12 weeks if there is no PSA decline from baseline
- Time to Radiographic Soft Tissue Progression Per Soft Tissue Rules of Prostate Cancer Working Group (PCWG)-modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review [ Time Frame: Up to approximately 28 months ]Time from randomization to radiographic soft tissue progression per PCWG-modified RECIST 1.1
- Number of Participants Who Experience an Adverse Event (AE) [ Time Frame: Up to approximately 28 months ]An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment
- Number of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE) [ Time Frame: Up to approximately 28 months ]The number of participants who discontinue study treatment due to an AE will be presented

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Has histologically- or cytologically-confirmed adenocarcinoma of the prostate without small cell histology
- Has prostate cancer progression while on androgen deprivation therapy (or post bilateral orchiectomy) within 6 months prior to screening
- Has current evidence of metastatic disease documented by either bone lesions on bone scan and/or soft tissue disease by computed tomography/magnetic resonance imaging (CT/MRI)
- Has received prior treatment with one (but not more than one) NHA (eg, abiraterone acetate, enzalutamide, apalutamide, or darolutamide) for metastatic hormone-sensitive prostate cancer (mHSPC) or castration-resistant prostate cancer (CRPC) and either a) progressed through treatment OR b) has become intolerant of the drug
- Has ongoing androgen deprivation with serum testosterone <50 ng/dL (<2.0 nM)
- Participants receiving bone resorptive therapy (including, but not limited to, bisphosphonate or denosumab) must have been on stable doses prior to randomization
- Participants must agree to the following during the study treatment period and for at least 120 days after the last dose of pembrolizumab or for at least 180 days after the last dose of docetaxel (whichever is longer): Refrain from donating sperm PLUS Use contraception unless confirmed to be azoospermic (vasectomized or secondary to medical cause)
- Participants must agree to use male condom when engaging in any activity that allows for passage of ejaculate to another person of any sex
- Has provided newly obtained core or excisional biopsy (obtained within 12 months of screening) from soft tissue not previously irradiated (samples from tumors progressing in a prior site of radiation are allowed). Participants with bone only or bone predominant disease may provide a bone biopsy sample
- Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 assessed within 7 days of randomization
Exclusion Criteria:
- Has a known additional malignancy that is progressing or has required active treatment in the last 3 years
- Has an active autoimmune disease that has required systemic treatment in past 2 years
- Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
- Has undergone major surgery including local prostate intervention (excluding prostate biopsy) within 28 days prior to randomization and not recovered adequately from the toxicities and/or complications
- Has a gastrointestinal disorder affecting absorption or is unable to swallow tablets/capsules
- Has an active infection (including tuberculosis) requiring systemic therapy
- Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis
- Has known active human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
- Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
- Has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients
- Has symptomatic congestive heart failure (New York Heart Association Class III or IV heart disease)
- Has had a prior anti-cancer monoclonal antibody (mAb) prior to randomization or who has not recovered (i.e., Grade ≤1 or at baseline) from AEs due to mAbs
- Has used herbal products that may have hormonal anti-prostate cancer activity and/or are known to decrease PSA levels (e.g. saw palmetto) prior to randomization
- Has received prior treatment with radium or other therapeutic radiopharmaceuticals for prostate cancer
- Has received prior therapy with an anti-programmed cell death-1 (anti-PD-1), anti-programmed cell death-ligand 1 (anti-PD-L1), or anti PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., cytotoxic T-lymphocyte-associated protein 4 [CTLA-4], OX-40, CD137)
- Has received prior treatment with docetaxel or another chemotherapy agent for mCRPC
- Has hypersensitivity to docetaxel or polysorbate 80
- Is currently receiving either strong or moderate inhibitors of cytochrome P450 (CYP)3A4 that cannot be discontinued for the duration of the study
- Has received prior targeted small molecule therapy or abiraterone acetate, enzalutamide, apalutamide, or darolutamide within 4 weeks prior to the first dose of study treatment, or has not recovered (i.e., Grade ≤1 or at baseline) from AEs due to a previously administered agent
- Has received prior radiotherapy to within 2 weeks of start of study treatment. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis
- Has received a live vaccine within 30 days prior to randomization
- Has received treatment with 5α reductase inhibitors (eg, finasteride or dutasteride), estrogens, and/or cyproterone within 4 weeks prior to randomization
- Has received prior treatment with ketoconazole for prostate cancer
- Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment
- Has a "superscan" bone scan
- Is expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study treatment
- Has had an allogenic tissue/solid organ transplant

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03834506
Contact: Toll Free Number | 1-888-577-8839 | Trialsites@merck.com |

United States, Alabama | |
University of South Alabama, Mitchell Cancer Institute ( Site 0065) | Recruiting |
Mobile, Alabama, United States, 36604 | |
Contact: Study Coordinator 251-665-8000 | |
United States, California | |
St. Joseph Heritage Healthcare ( Site 0069) | Recruiting |
Fullerton, California, United States, 92835 | |
Contact: Study Coordinator 714-446-5642 | |
University of Southern California Norris Comprehensive Cancer Center ( Site 0061) | Recruiting |
Los Angeles, California, United States, 90033 | |
Contact: Study Coordinator 323-865-3000 | |
USC Norris Oncology Hematology Newport Beach ( Site 0093) | Recruiting |
Newport Beach, California, United States, 92663 | |
Contact: Study Coordinator 323-865-3000 | |
University of California San Francisco ( Site 0023) | Recruiting |
San Francisco, California, United States, 94158 | |
Contact: Study Coordinator 415-502-5051 | |
United States, Colorado | |
University of Colorado Cancer Center ( Site 0022) | Recruiting |
Aurora, Colorado, United States, 80045 | |
Contact: Study Coordinator 720-848-0603 | |
United States, Connecticut | |
Yale Cancer Center ( Site 0038) | Recruiting |
New Haven, Connecticut, United States, 06510 | |
Contact: Study Coordinator 203-785-6821 | |
United States, Florida | |
Moffitt Cancer Center ( Site 0080) | Recruiting |
Tampa, Florida, United States, 33612 | |
Contact: Study Coordinator 813-745-3822 | |
United States, Georgia | |
Georgia Cancer Center at Augusta University ( Site 0026) | Recruiting |
Augusta, Georgia, United States, 30912 | |
Contact: Study Coordinator 706-721-2505 | |
United States, Illinois | |
Mount Sinai Hospital Medical Center ( Site 0042) | Recruiting |
Chicago, Illinois, United States, 60608 | |
Contact: Study Coordinator 872-222-7830 | |
United States, Indiana | |
Methodist Hospital- Merriillville ( Site 0008) | Completed |
Merrillville, Indiana, United States, 46410 | |
United States, Michigan | |
Karmanos Cancer Institute ( Site 0077) | Completed |
Detroit, Michigan, United States, 48201 | |
Henry Ford Health System ( Site 0039) | Recruiting |
Detroit, Michigan, United States, 48202-2608 | |
Contact: Study Coordinator 313-916-8862 | |
Cancer & Hematology Centers of Western Michigan ( Site 0013) | Recruiting |
Grand Rapids, Michigan, United States, 49503 | |
Contact: Study Coordinator 616-954-9800 | |
United States, Missouri | |
Washington University School of Medicine ( Site 0057) | Recruiting |
Saint Louis, Missouri, United States, 63110 | |
Contact: Study Coordinator 314-747-1343 | |
United States, Montana | |
St. Vincent Frontier Cancer Center ( Site 0016) | Recruiting |
Billings, Montana, United States, 59102 | |
Contact: Study Coordinator 406-238-6290 | |
United States, Nebraska | |
Nebraska Cancer Specialists ( Site 0034) | Recruiting |
Omaha, Nebraska, United States, 68130 | |
Contact: Study Coordinator 402-691-6971 | |
United States, Nevada | |
Comprehensive Cancer Centers of Nevada ( Site 0092) | Recruiting |
Las Vegas, Nevada, United States, 89169 | |
Contact: Study Coordinator 702-952-3400 | |
United States, New Jersey | |
John Theurer Cancer Center at Hackensack University Medical Center ( Site 0004) | Recruiting |
Hackensack, New Jersey, United States, 07601 | |
Contact: Study Coordinator 551-996-5900 | |
United States, New York | |
Associated Medical Professionals of NY ( Site 0060) | Recruiting |
Syracuse, New York, United States, 13210 | |
Contact: Study Coordinator 315-478-4185x7794 | |
United States, North Carolina | |
Duke Cancer Center ( Site 0010) | Recruiting |
Durham, North Carolina, United States, 27710 | |
Contact: Study Coordinator 981-681-7460 | |
W. G. Bill Hefner VA Medical Center ( Site 0029) | Recruiting |
Salisbury, North Carolina, United States, 28144 | |
Contact: Study Coordinator 704-638-9000 | |
United States, Ohio | |
University Hospitals Cleveland Medical Center ( Site 0036) | Recruiting |
Cleveland, Ohio, United States, 44106 | |
Contact: Study Coordinator 216-844-6031 | |
United States, Oregon | |
Oregon Health Sciences University ( Site 0031) | Recruiting |
Portland, Oregon, United States, 97239 | |
Contact: Study Coordinator 503-494-8311 | |
United States, South Carolina | |
Carolina Urologic Research Center ( Site 0070) | Recruiting |
Myrtle Beach, South Carolina, United States, 29572 | |
Contact: Study Coordinator 8434491010257 | |
United States, Virginia | |
Inova Schar Cancer Institute ( Site 0006) | Recruiting |
Fairfax, Virginia, United States, 22031-4867 | |
Contact: Study Coordinator 571-472-0625 | |
Virginia Cancer Institute ( Site 0052) | Completed |
Richmond, Virginia, United States, 23230 | |
Blue Ridge Cancer Care ( Site 0086) | Recruiting |
Roanoke, Virginia, United States, 24014 | |
Contact: Study Coordinator 540-982-0237 | |
Argentina | |
Centro de Oncologia e Investigacion Buenos Aires COIBA ( Site 1013) | Recruiting |
Berazategui, Buenos Aires, Argentina, B1884BBF | |
Contact: Study Coordinator +541142262013 | |
Instituto de Investigaciones Clinicas ( Site 1000) | Recruiting |
Mar del Plata, Buenos Aires, Argentina, B7600FZN | |
Contact: Study Coordinator +542234963224 | |
Centro de Diagnostico Urologico ( Site 1008) | Recruiting |
Buenos Aires, Caba, Argentina, C1120AAT | |
Contact: Study Coordinator +5491149898569 | |
Hospital Britanico de Buenos Aires ( Site 1006) | Recruiting |
Buenos Aires, Caba, Argentina, C1280AEB | |
Contact: Study Coordinator +541143096400 | |
Instituto Medico Alexander Fleming ( Site 1010) | Recruiting |
Buenos Aires, Caba, Argentina, C1426ANZ | |
Contact: Study Coordinator 5491153288346 | |
Sanatorio Parque ( Site 1002) | Recruiting |
Rosario, Santa Fe, Argentina, S2000DSV | |
Contact: Study Coordinator +54341420-0230 | |
Instituto de Investigaciones Metabolicas [Buenos Aires, Argentina] ( Site 1011) | Recruiting |
Buenos Aires, Argentina, C1012AAR | |
Contact: Study Coordinator +5491130051657 | |
Hospital Aleman ( Site 1004) | Recruiting |
Buenos Aires, Argentina, C1118AAT | |
Contact: Study Coordinator +5411482770003036 | |
CEMAIC ( Site 1014) | Recruiting |
Cordoba, Argentina, X5008HHW | |
Contact: Study Coordinator +543514766837 | |
Australia, New South Wales | |
St George Hospital ( Site 0157) | Recruiting |
Kogarah, New South Wales, Australia, 2217 | |
Contact: Study Coordinator +61291133830 | |
Macquarie University ( Site 0151) | Recruiting |
Macquarie University, New South Wales, Australia, 2109 | |
Contact: Study Coordinator +61298123000 | |
Port Macquarie Base Hospital ( Site 0153) | Recruiting |
Port Macquarie, New South Wales, Australia, 2444 | |
Contact: Study Coordinator +61265801818 | |
Calvary Mater Newcastle ( Site 0148) | Recruiting |
Waratah, New South Wales, Australia, 2298 | |
Contact: Study Coordinator +61249211211 | |
Australia, Queensland | |
Redcliffe Hospital ( Site 0161) | Recruiting |
Redcliffe, Queensland, Australia, 4020 | |
Contact: Study Coordinator +61738837426 | |
John Flynn Hospital & Medical Centre ( Site 0164) | Recruiting |
Tugun, Queensland, Australia, 4224 | |
Contact: Study Coordinator +61755989733 | |
Australia, Western Australia | |
Hollywood Private Hospital ( Site 0163) | Recruiting |
Nedlands, Western Australia, Australia, 6009 | |
Contact: Study Coordinator +61893891437 | |
Austria | |
Ordensklinikum Linz GmbH Elisabethinen ( Site 0373) | Recruiting |
Linz, Oberosterreich, Austria, 4020 | |
Contact: Study Coordinator +4373276764600 | |
Medizinische Universitat Graz ( Site 0374) | Recruiting |
Graz, Steiermark, Austria, 8036 | |
Contact: Study Coordinator +4331638580271 | |
SCRI-CCCIT GesmbH ( Site 0371) | Recruiting |
Salzburg, Austria, 5020 | |
Contact: Study Coordinator +435725525801 | |
Medizinische Universitaet Wien ( Site 0375) | Recruiting |
Wien, Austria, 1090 | |
Contact: Study Coordinator +4314040026220 | |
Brazil | |
Hospital de Caridade de Ijui ( Site 1038) | Recruiting |
Ijui, Rio Grande Do Sul, Brazil, 98700-000 | |
Contact: Study Coordinator +555533319393 | |
Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da Pucrs ( Site 1021) | Recruiting |
Porto Alegre, Rio Grande Do Sul, Brazil, 90610-000 | |
Contact: Study Coordinator +555133203039 | |
Centro de Novos Tratamentos Itajai - Clinica de Neoplasias Litoral ( Site 1035) | Recruiting |
Itajai, Santa Catarina, Brazil, 88301-215 | |
Contact: Study Coordinator +554733485093 | |
Hospital de Base de Sao Jose de Rio Preto ( Site 1022) | Recruiting |
Sao Jose do Rio Preto, Sao Paulo, Brazil, 15090-000 | |
Contact: Study Coordinator +5517981191186 | |
A.C. Camargo Cancer Center ( Site 1026) | Recruiting |
Sao Paulo, Brazil, 01509-900 | |
Contact: Study Coordinator +5511218950002981 | |
Canada, Nova Scotia | |
Nova Scotia Health Authority QEII-HSC ( Site 0114) | Recruiting |
Halifax, Nova Scotia, Canada, B3H 2Y9 | |
Contact: Study Coordinator 9024736106 | |
Canada, Ontario | |
Juravinski Cancer Centre ( Site 0116) | Recruiting |
Hamilton, Ontario, Canada, L8V 1C3 | |
Contact: Study Coordinator 905387949563123 | |
Grand River Hospital ( Site 0120) | Recruiting |
Kitchener, Ontario, Canada, N2G 1G3 | |
Contact: Study Coordinator 51974943705745 | |
Lakeridge Health ( Site 0117) | Recruiting |
Oshawa, Ontario, Canada, L1G 2B9 | |
Contact: Study Coordinator 9055768711 | |
Sunnybrook Research Institute ( Site 0108) | Recruiting |
Toronto, Ontario, Canada, M4N 3M5 | |
Contact: Study Coordinator 41648050005739 | |
Princess Margaret Cancer Centre ( Site 0107) | Recruiting |
Toronto, Ontario, Canada, M5G 2M9 | |
Contact: Study Coordinator 4169464522 | |
Canada, Quebec | |
CIUSSS du Bas Saint Laurent - Hopital Regional de Rimouski ( Site 0102) | Recruiting |
Rimouski, Quebec, Canada, G5L 5T1 | |
Contact: Study Coordinator 41872430008465 | |
CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0105) | Recruiting |
Sherbrooke, Quebec, Canada, J1H 5N4 | |
Contact: Study Coordinator 819346111012811 | |
Canada | |
CHU de Quebec-Universite Laval-Hotel Dieu de Quebec ( Site 0103) | Recruiting |
Quebec, Canada, G1R 2J6 | |
Contact: Study Coordinator 418525444420414 | |
Chile | |
Rey y Oreilly Limitada ( Site 1048) | Recruiting |
Temuco, Araucania, Chile, 4810148 | |
Contact: Study Coordinator +56957983173 | |
Sociedad de Investigaciones Medicas Limitadas ( Site 1041) | Recruiting |
Temuco, Araucania, Chile, 4810469 | |
Contact: Study Coordinator +56994443272 | |
Fundacion Arturo Lopez Perez ( Site 1049) | Recruiting |
Santiago, Region M. De Santiago, Chile, 7500921 | |
Contact: Study Coordinator +56224457254 | |
Pontificia Universidad Catolica de Chile ( Site 1047) | Recruiting |
Santiago, Region M. De Santiago, Chile, 8330032 | |
Contact: Study Coordinator +56942477513 | |
Bradford Hill Centro de Investigaciones Clinicas ( Site 1044) | Recruiting |
Santiago, Region M. De Santiago, Chile, 8420383 | |
Contact: Study Coordinator +56954240723 | |
Centro de Investigaciones Clinicas Vina del Mar ( Site 1042) | Recruiting |
Vina del Mar, Valparaiso, Chile, 2540488 | |
Contact: Study Coordinator +56993236162 | |
China, Beijing | |
Peking University First Hospital ( Site 1303) | Recruiting |
Beijing, Beijing, China, 100034 | |
Contact: Study Coordinator +8613910688432 | |
Beijing Cancer Hospital ( Site 1305) | Recruiting |
Beijing, Beijing, China, 100142 | |
Contact: Study Coordinator +8613910571565 | |
China, Guangdong | |
Sun Yat Sen Memorial Hospital ( Site 1323) | Recruiting |
Guangzhou, Guangdong, China, 510220 | |
Contact: Study Coordinator 02081332371 | |
China, Hubei | |
Hubei Cancer Hospital ( Site 1329) | Recruiting |
Wuhan, Hubei, China, 430079 | |
Contact: Study Coordinator +8602787671805 | |
China, Jiangsu | |
Nanjing Drum Tower Hospital ( Site 1312) | Recruiting |
Nanjing, Jiangsu, China, 210008 | |
Contact: Study Coordinator +86 02583106666 | |
China, Shanghai | |
Fudan University Shanghai Cancer Center ( Site 1300) | Recruiting |
Shanghai, Shanghai, China, 200032 | |
Contact: Study Coordinator +8613701663571 | |
Zhongshan Hospital Fudan University ( Site 1301) | Recruiting |
Shanghai, Shanghai, China, 200032 | |
Contact: Study Coordinator +8613681971306 | |
China, Zhejiang | |
Zhejiang Provincial People's Hospital ( Site 1310) | Recruiting |
Hangzhou, Zhejiang, China, 310014 | |
Contact: Study Coordinator +8657185893646 | |
Colombia | |
Hospital Pablo Tobon Uribe ( Site 1066) | Completed |
Medellin, Antioquia, Colombia, 050034 | |
Biomelab S A S ( Site 1067) | Completed |
Barranquilla, Atlantico, Colombia, 080002 | |
Clinica de la Costa Ltda. ( Site 1073) | Recruiting |
Barranquilla, Atlantico, Colombia, 080020 | |
Contact: Study Coordinator +573369940209 | |
Sociedad de Oncología Y Hematología del Cesar S.A.S. ( Site 1068) | Recruiting |
Valledupar, Cesar, Colombia, 200001 | |
Contact: Study Coordinator +5755602310 | |
Oncomedica S.A. ( Site 1057) | Recruiting |
Monteria, Cordoba, Colombia, 230002 | |
Contact: Study Coordinator +57478543441305 | |
Clinica Colsanitas S.A. Sede Clinica Universitaria Colombia ( Site 1062) | Recruiting |
Bogota, Distrito Capital De Bogota, Colombia, 110311 | |
Contact: Study Coordinator +573107697775 | |
Instituto Nacional de Cancerologia E.S.E ( Site 1061) | Recruiting |
Bogota, Distrito Capital De Bogota, Colombia, 110321 | |
Contact: Study Coordinator +573173760440 | |
Oncologos del Occidente S.A. ( Site 1072) | Recruiting |
Pereira, Risaralda, Colombia, 660001 | |
Contact: Study Coordinator +573155313926 | |
Centro Medico Imbanaco de Cali S.A ( Site 1064) | Recruiting |
Cali, Valle Del Cauca, Colombia, 760042 | |
Contact: Study Coordinator +5725146015 | |
Hemato Oncologos S.A. ( Site 1065) | Recruiting |
Cali, Valle Del Cauca, Colombia, 760042 | |
Contact: Study Coordinator +573105395661 | |
France | |
C.H. de Saint Quentin ( Site 0481) | Recruiting |
Saint Quentin, Aisne, France, 02321 | |
Contact: Study Coordinator +33323067224 | |
Clinique Sainte Anne ( Site 0431) | Recruiting |
Strasbourg, Alsace, France, 67000 | |
Contact: Study Coordinator +33388453570 | |
Centre Jean Perrin ( Site 0434) | Recruiting |
Clermont-Ferrand, Auvergne, France, 63011 | |
Contact: Study Coordinator +33473278131 | |
Centre Leon Berard ( Site 0422) | Recruiting |
Lyon, Auvergne, France, 69373 | |
Contact: Study Coordinator +33478782643 | |
Institut Paoli Calmettes. ( Site 0419) | Recruiting |
Marseille, Bouches-du-Rhone, France, 13009 | |
Contact: Study Coordinator +33491223760 | |
CHU Jean Minjoz ( Site 0423) | Recruiting |
Besancon, Doubs, France, 25000 | |
Contact: Study Coordinator +33370632440 | |
CHU de Brest -Site Hopital Morvan ( Site 0441) | Recruiting |
Brest, Finistere, France, 29200 | |
Contact: Study Coordinator +33298223395 | |
Institut Bergonie ( Site 0421) | Recruiting |
Bordeaux, Gironde, France, 33076 | |
Contact: Study Coordinator +33556333333 | |
Institut Claudius Regaud IUCT Oncopole ( Site 0418) | Recruiting |
Toulouse, Haute-Garonne, France, 31059 | |
Contact: Study Coordinator +33531155151 | |
Hopital Foch ( Site 0428) | Recruiting |
Suresnes, Hauts-de-Seine, France, 92151 | |
Contact: Study Coordinator +33146253581 | |
Institut De Cancerologie De L Ouest ( Site 0448) | Recruiting |
Saint Herblain, Loire-Atlantique, France, 44805 | |
Contact: Study Coordinator +33240679939 | |
Centre Hospitalier Regional du Orleans ( Site 0430) | Recruiting |
Orleans, Loiret, France, 45100 | |
Contact: Study Coordinator +33238229652 | |
Centre D Oncologie de Gentilly ( Site 0432) | Recruiting |
Nancy, Meurthe-et-Moselle, France, 54100 | |
Contact: Study Coordinator +33383935005 | |
Institut Sainte Catherine ( Site 0447) | Recruiting |
Avignon, Provence-Alpes-Cote-d Azur, France, 84000 | |
Contact: Study Coordinator +33490276090 | |
C.H.U. Lyon Sud ( Site 0436) | Recruiting |
Pierre Benite, Rhone, France, 69310 | |
Contact: Study Coordinator +33478864324 | |
CHU Amiens Picardie Site Sud Amiens ( Site 0438) | Recruiting |
Amiens, Somme, France, 80000 | |
Contact: Study Coordinator +33322455499 | |
Institut Gustave Roussy ( Site 0416) | Recruiting |
Villejuif, Val-de-Marne, France, 94800 | |
Contact: Study Coordinator +33142114559 | |
Institut Mutualiste Montsouris ( Site 0446) | Recruiting |
Paris, France, 75014 | |
Contact: Study Coordinator +33156616242 | |
Germany | |
Universitaetsklinikum Freiburg - Medizinische Klinik ( Site 0304) | Recruiting |
Freiburg, Baden-Wurttemberg, Germany, 79106 | |
Contact: Study Coordinator +4976127028930 | |
Universitaetsklinikum in Mannheim ( Site 0314) | Recruiting |
Mannheim, Baden-Wurttemberg, Germany, 68167 | |
Contact: Study Coordinator +496213833934 | |
Studienpraxis Urologie ( Site 0309) | Recruiting |
Nuertingen, Baden-Wurttemberg, Germany, 72622 | |
Contact: Study Coordinator +491703809223 | |
Universitaetsklinik fuer Urologie ( Site 0307) | Recruiting |
Tuebingen, Baden-Wurttemberg, Germany, 72076 | |
Contact: Study Coordinator +4970712986613 | |
Klinikum Rechts der Isar ( Site 0300) | Recruiting |
Muenchen, Bayern, Germany, 81675 | |
Contact: Study Coordinator +498941402522 | |
Universitaetsklinik der Paracelsus Medizinischen Privatuniversitaet ( Site 0318) | Recruiting |
Nuernberg, Bayern, Germany, 90419 | |
Contact: Study Coordinator +49911398114729 | |
Universitaetsklinikum Wuerzburg ( Site 0302) | Recruiting |
Wuerzburg, Bayern, Germany, 97080 | |
Contact: Study Coordinator +499312010 | |
Universitaetsklinikum Goettingen ( Site 0345) | Recruiting |
Goettingen, Niedersachsen, Germany, 37075 | |
Contact: Study Coordinator +4955139175669 | |
Uniklinik RWTH Aachen ( Site 0308) | Recruiting |
Aachen, Nordrhein-Westfalen, Germany, 52074 | |
Contact: Study Coordinator +492418036576 | |
Universitaetsklinikum des Saarlandes ( Site 0348) | Recruiting |
Homburg, Saarland, Germany, 66421 | |
Contact: Study Coordinator +4968411624777 | |
Universitaetsklinikum Jena ( Site 0305) | Recruiting |
Jena, Thuringen, Germany, 07747 | |
Contact: Study Coordinator +491711421827 | |
Charite Universitaetsmedizin Berlin ( Site 0301) | Recruiting |
Berlin, Germany, 10117 | |
Contact: Study Coordinator +4930450515288 | |
Ireland | |
Cork University Hospital ( Site 0727) | Recruiting |
Cork, Ireland, T12 YE02 | |
Contact: Study Coordinator +353214920052 | |
Tallaght University Hospital ( Site 0730) | Recruiting |
Dublin, Ireland, D24 NROA | |
Contact: Study Coordinator +35314144299 | |
Mid Western Cancer Centre ( Site 0728) | Recruiting |
Limerick, Ireland | |
Contact: Study Coordinator +35361485159 | |
Israel | |
Soroka Medical Center ( Site 0548) | Recruiting |
Beer Sheva, Israel, 8410101 | |
Contact: Study Coordinator +97286244127 | |
Assaf Harofeh MC ( Site 0547) | Completed |
Beer Yaakov-Zerifin, Israel, 7030001 | |
Rambam Medical Center ( Site 0543) | Recruiting |
Haifa, Israel, 3109601 | |
Contact: Study Coordinator +97236973413 | |
Hadassah Ein Kerem Medical Center ( Site 0546) | Recruiting |
Jerusalem, Israel, 9112001 | |
Contact: Study Coordinator +972505172315 | |
Meir Medical Center ( Site 0544) | Recruiting |
Kfar Saba, Israel, 4428164 | |
Contact: Study Coordinator +97297471606 | |
Rabin Medical Center ( Site 0545) | Recruiting |
Petach-Tikwa, Israel, 4941492 | |
Contact: Study Coordinator +97239377973 | |
Chaim Sheba Medical Center ( Site 0541) | Recruiting |
Ramat Gan, Israel, 5262000 | |
Contact: Study Coordinator +97235309542 | |
Sourasky Medical Center ( Site 0542) | Suspended |
Tel Aviv, Israel, 6423906 | |
Italy | |
Istituto Clinico Humanitas Research Hospital ( Site 0452) | Recruiting |
Rozzano, Milano, Italy, 20089 | |
Contact: Study Coordinator +390282244061 | |
Azienda Ospedaliera Cannizzaro ( Site 0458) | Recruiting |
Catania, Italy, 95126 | |
Contact: Study Coordinator +390957262082 | |
A.O. Universitaria di Modena ( Site 0454) | Recruiting |
Modena, Italy, 41100 | |
Contact: Study Coordinator +390594222648 | |
Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 0457) | Recruiting |
Napoli, Italy, 80131 | |
Contact: Study Coordinator +390815903637 | |
Azienda Ospedaliera San Camillo Forlanini ( Site 0455) | Recruiting |
Roma, Italy, 00152 | |
Contact: Study Coordinator +390658704356 | |
Azienda Ospedaliera Santa Maria Terni ( Site 0456) | Recruiting |
Terni, Italy, 05100 | |
Contact: Study Coordinator +390744205410 | |
Presidio Ospedaliero Santa Chiara ( Site 0451) | Recruiting |
Trento, Italy, 38122 | |
Contact: Study Coordinator +390461902121 | |
Japan | |
National Cancer Center Hospital East ( Site 0702) | Recruiting |
Kashiwa, Chiba, Japan, 277-8577 | |
Contact: Study Coordinator +81471331111 | |
Toho University Sakura Medical Center ( Site 0703) | Recruiting |
Sakura, Chiba, Japan, 285-8741 | |
Contact: Study Coordinator +81434628811 | |
National Hospital Organization Shikoku Cancer Center ( Site 0716) | Recruiting |
Matsuyama, Ehime, Japan, 791-0280 | |
Contact: Study Coordinator +81899991111 | |
Kanazawa University Hospital ( Site 0701) | Recruiting |
Kanazawa, Ishikawa, Japan, 920-8641 | |
Contact: Study Coordinator +81762652000 | |
Kitasato University Hospital ( Site 0705) | Recruiting |
Sagamihara, Kanagawa, Japan, 252-0375 | |
Contact: Study Coordinator +81427788111 | |
Yokohama City University Medical Center ( Site 0706) | Recruiting |
Yokohama, Kanagawa, Japan, 232-0024 | |
Contact: Study Coordinator +81452615656 | |
Nara Medical University Hospital ( Site 0715) | Active, not recruiting |
Kashihara, Nara, Japan, 634-8522 | |
Kindai University Hospital ( Site 0714) | Recruiting |
Osakasayama, Osaka, Japan, 589-8511 | |
Contact: Study Coordinator +81723660221 | |
Osaka University Hospital ( Site 0713) | Recruiting |
Suita, Osaka, Japan, 565-0871 | |
Contact: Study Coordinator +81668795111 | |
Saitama Medical University International Medical Center ( Site 0708) | Recruiting |
Hidaka, Saitama, Japan, 1932 | |
Contact: Study Coordinator +81429844111 | |
Dokkyo Medical University Saitama Medical Center ( Site 0707) | Recruiting |
Koshigaya, Saitama, Japan, 343-8555 | |
Contact: Study Coordinator +81489651111 | |
Hamamatsu University Hospital ( Site 0720) | Recruiting |
Hamamatsu, Shizuoka, Japan, 431-3192 | |
Contact: Study Coordinator +81534352111 | |
Yamaguchi University Hospital ( Site 0717) | Recruiting |
Ube, Yamaguchi, Japan, 755-8505 | |
Contact: Study Coordinator +81836222111 | |
Chiba Cancer Center ( Site 0704) | Recruiting |
Chiba, Japan, 260-8717 | |
Contact: Study Coordinator +81432645431 | |
Kyushu University Hospital ( Site 0718) | Recruiting |
Fukuoka, Japan, 812-8582 | |
Contact: Study Coordinator +81926411151 | |
University of Miyazaki Hospital ( Site 0721) | Recruiting |
Miyazaki, Japan, 889-1692 | |
Contact: Study Coordinator +81985851510 | |
Nagasaki University Hospital ( Site 0719) | Recruiting |
Nagasaki, Japan, 852-8501 | |
Contact: Study Coordinator +81958197200 | |
Toranomon Hospital ( Site 0711) | Recruiting |
Tokyo, Japan, 105-8470 | |
Contact: Study Coordinator +81335881111 | |
Nippon Medical School Hospital ( Site 0709) | Recruiting |
Tokyo, Japan, 113-8603 | |
Contact: Study Coordinator +81338222131 | |
Keio University Hospital ( Site 0710) | Recruiting |
Tokyo, Japan, 160-8582 | |
Contact: Study Coordinator +81333531211 | |
Korea, Republic of | |
National Cancer Center ( Site 0174) | Recruiting |
Goyang-si, Kyonggi-do, Korea, Republic of, 10408 | |
Contact: Study Coordinator +82319201740 | |
Seoul National University Bundang Hospital ( Site 0175) | Recruiting |
Seongnam-si, Kyonggi-do, Korea, Republic of, 13620 | |
Contact: Study Coordinator +82317872640 | |
Seoul National University Hospital ( Site 0171) | Recruiting |
Seoul, Korea, Republic of, 03080 | |
Contact: Study Coordinator +82260725189 | |
Asan Medical Center ( Site 0176) | Recruiting |
Seoul, Korea, Republic of, 05505 | |
Contact: Study Coordinator +82230103734 | |
Samsung Medical Center ( Site 0172) | Completed |
Seoul, Korea, Republic of, 06351 | |
Netherlands | |
Medisch Centrum Leeuwarden ( Site 0477) | Recruiting |
Leeuwarden, Fryslan, Netherlands, 8934 AD | |
Contact: Study Coordinator +31582866010 | |
Ziekenhuis Gelderse Vallei ( Site 0485) | Recruiting |
Ede, Gelderland, Netherlands, 6716 RP | |
Contact: Study Coordinator +31318434343 | |
Radboud University Medical Center ( Site 0470) | Recruiting |
Nijmegen, Gelderland, Netherlands, 6525 GA | |
Contact: Study Coordinator +31243610353 | |
VieCuri Medisch Centrum ( Site 0487) | Recruiting |
Venlo, Limburg, Netherlands, 5912 BL | |
Contact: Study Coordinator +31773205634 | |
Jeroen Bosch Ziekenhuis ( Site 1200) | Recruiting |
Den Bosch, Noord-Brabant, Netherlands, 5223 GZ | |
Contact: Study Coordinator +31735536250 | |
Catharina Ziekenhuis ( Site 0472) | Recruiting |
Eindhoven, Noord-Brabant, Netherlands, 5623 EJ | |
Contact: Study Coordinator +31402396622 | |
Antoni van Leeuwenhoek Ziekenhuis ( Site 0480) | Recruiting |
Amsterdam, Noord-Holland, Netherlands, 1066 CX | |
Contact: Study Coordinator +31205122569 | |
Ziekenhuis Hilversum ( Site 0466) | Recruiting |
Hilversum, Noord-Holland, Netherlands, 1213 XZ | |
Contact: Study Coordinator +31887531150 | |
Ziekenhuisgroep Twente ( Site 0469) | Recruiting |
Hengelo, Overijssel, Netherlands, 7555 DL | |
Contact: Study Coordinator +31887087076 | |
Reinier de Graaf Groep ( Site 0484) | Recruiting |
Delft, Zuid-Holland, Netherlands, 2625 AD | |
Contact: Study Coordinator +31152603060 | |
Hagaziekenhuis ( Site 1201) | Recruiting |
Den Haag, Zuid-Holland, Netherlands, 2545 AA | |
Contact: Study Coordinator +31702100000 | |
Russian Federation | |
Chelyabinsk Regional Clinical Oncological Dispensary ( Site 0565) | Recruiting |
Chelyabinsk, Chelyabinskaya Oblast, Russian Federation, 454087 | |
Contact: Study Coordinator +79127949047 | |
Krasnoyarsk Regional Clinical Oncological Dispensary ( Site 0585) | Recruiting |
Krasnoyarsk, Krasnoyarskiy Kray, Russian Federation, 660133 | |
Contact: Study Coordinator +79135349316 | |
SBIH City clinical hospital named after D.D. Pletniov ( Site 0575) | Recruiting |
Moscow, Moskva, Russian Federation, 105077 | |
Contact: Study Coordinator +79164091611 | |
Russian Scientific Center of Radiology ( Site 0559) | Recruiting |
Moscow, Moskva, Russian Federation, 117485 | |
Contact: Study Coordinator +79166590224 | |
Central Clinical Hospital with Polyclinic ( Site 0562) | Recruiting |
Moscow, Moskva, Russian Federation, 121359 | |
Contact: Study Coordinator +74993241114 | |
National Medical Research Radiological Center ( Site 0556) | Recruiting |
Moscow, Moskva, Russian Federation, 125284 | |
Contact: Study Coordinator +89859975250 | |
Volga District Medical Center Federal Medical and Biological Agency ( Site 0572) | Recruiting |
Nizhny Novgorod, Nizhegorodskaya Oblast, Russian Federation, 603074 | |
Contact: Study Coordinator +78314216969 | |
Omsk Clinical Oncology Dispensary ( Site 0568) | Recruiting |
Omsk, Omskaya Oblast, Russian Federation, 644013 | |
Contact: Study Coordinator +79139885114 | |
SBHI Samara Regional Clinical Oncology Dispensary ( Site 0576) | Completed |
Samara, Samarskaya Oblast, Russian Federation, 443031 | |
Clinical Research Center of specialized types medical care-Oncology ( Site 0570) | Recruiting |
Saint Petersburg, Sankt-Peterburg, Russian Federation, 197758 | |
Contact: Study Coordinator +79219697585 | |
Russian Scientific Center of Radiology and Surgical Technologies ( Site 0567) | Completed |
Saint Petersburg, Sankt-Peterburg, Russian Federation, 197758 | |
SPb SBHI City Clinical Oncological Dispensary ( Site 0571) | Recruiting |
Saint Petersburg, Sankt-Peterburg, Russian Federation, 198255 | |
Contact: Study Coordinator +78129482951 | |
Leningrad Regional Oncology Center ( Site 0588) | Recruiting |
Saint-Petersburg, Sankt-Peterburg, Russian Federation, 188663 | |
Contact: Study Coordinator +79687829085 | |
Tomsk National Research Medical Center of Russian Academy of Sciences ( Site 0579) | Completed |
Tomsk, Tomskaya Oblast, Russian Federation, 634050 | |
Spain | |
Instituto Catalan de Oncologia - ICO ( Site 0330) | Recruiting |
L Hospitalet De Llobregat, Barcelona, Spain, 08908 | |
Contact: Study Coordinator +34932607744 | |
Hospital Consorci Sanitari Parc Tauli ( Site 0335) | Recruiting |
Sabadell, Barcelona, Spain, 08208 | |
Contact: Study Coordinator +34937240084 | |
Hospital Universitario Marques de Valdecilla ( Site 0336) | Recruiting |
Santander, Cantabria, Spain, 39008 | |
Contact: Study Coordinator +34942202525 | |
Hospital Josep Trueta ( Site 0321) | Recruiting |
Girona, Gerona, Spain, 17007 | |
Contact: Study Coordinator +349722258284028 | |
Hospital del Mar ( Site 0333) | Recruiting |
Barcelona, Spain, 08003 | |
Contact: Study Coordinator +34932483139 | |
Hospital Clinic ( Site 0323) | Recruiting |
Barcelona, Spain, 08036 | |
Contact: Study Coordinator +34932275402 | |
Hospital Universitario Ramon y Cajal ( Site 0328) | Recruiting |
Madrid, Spain, 28034 | |
Contact: Study Coordinator +34913368263 | |
Hospital Clinico San Carlos ( Site 0324) | Recruiting |
Madrid, Spain, 28040 | |
Contact: Study Coordinator +349133030007545 | |
Hospital Universitario HM Sanchinarro ( Site 0322) | Recruiting |
Madrid, Spain, 28050 | |
Contact: Study Coordinator +34917567984 | |
Hospital Universitario Virgen de la Victoria ( Site 0337) | Recruiting |
Malaga, Spain, 29016 | |
Contact: Study Coordinator +34951032249 | |
Hospital Virgen del Rocio ( Site 0329) | Recruiting |
Sevilla, Spain, 41013 | |
Contact: Study Coordinator +34955012000 | |
Taiwan | |
National Cheng Kung University Hospital ( Site 0134) | Completed |
Tainen, Tainan, Taiwan, 704 | |
China Medical University Hospital ( Site 0132) | Recruiting |
Taichung, Taiwan, 404 | |
Contact: Study Coordinator +886422052121 | |
Taichung Veterans General Hospital ( Site 0133) | Recruiting |
Taichung, Taiwan, 40705 | |
Contact: Study Coordinator +886423741215 | |
National Taiwan University Hospital ( Site 0131) | Recruiting |
Taipei, Taiwan, 10048 | |
Contact: Study Coordinator 886223123456#71656 | |
Taipei Veterans General Hospital ( Site 0135) | Recruiting |
Taipei, Taiwan, 11217 | |
Contact: Study Coordinator +886228757519 | |
United Kingdom | |
University Hospitals Bristol NHS Foundation Trust ( Site 0530) | Recruiting |
Bristol, Bristol, City Of, United Kingdom, BS2 8ED | |
Contact: Study Coordinator +441173422418 | |
Cambridge University Hospitals NHS Trust ( Site 0540) | Recruiting |
Cambridge, Cambridgeshire, United Kingdom, CB2 0QQ | |
Contact: Study Coordinator +441223217020 | |
Torbay Hospital ( Site 0532) | Recruiting |
Torquay, Devon, United Kingdom, TQ2 7AA | |
Contact: Study Coordinator +4401803655376 | |
Weston Park Hospital ( Site 0539) | Recruiting |
Sheffield, England, United Kingdom, S10 2SJ | |
Contact: Study Coordinator +441142265364 | |
Royal Marsden Hospital ( Site 0526) | Recruiting |
Sutton, England, United Kingdom, SM2 5PT | |
Contact: Study Coordinator +442086427979 | |
Mount Vernon Cancer Centre ( Site 0536) | Recruiting |
Northwood, Hertfordshire, United Kingdom, HA6 2RN | |
Contact: Study Coordinator +442038262136 | |
Barts Cancer Institute ( Site 0483) | Recruiting |
London, London, City Of, United Kingdom, EC1A 7BE | |
Contact: Study Coordinator +442078828505 | |
University of North Midlands NHS Foundation Trust ( Site 0527) | Recruiting |
Stoke-on-Trent, Staffordshire, United Kingdom, ST4 6QG | |
Contact: Study Coordinator +441782675616 |
Study Director: | Medical Director | Merck Sharp & Dohme Corp. |
Responsible Party: | Merck Sharp & Dohme Corp. |
ClinicalTrials.gov Identifier: | NCT03834506 |
Other Study ID Numbers: |
3475-921 2018-004116-22 ( EudraCT Number ) MK-3475-921 ( Other Identifier: Merck ) KEYNOTE-921 ( Other Identifier: Merck ) JAPAC-CTI ( Registry Identifier: 194831 ) |
First Posted: | February 8, 2019 Key Record Dates |
Last Update Posted: | February 24, 2021 |
Last Verified: | February 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf |
URL: | http://engagezone.msd.com/ds_documentation.php |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Programmed Cell Death-1 (PD1, PD-1) Programmed Death-Ligand 1 (PDL1, PD-L1) |
Prostatic Neoplasms Genital Neoplasms, Male Urogenital Neoplasms Neoplasms by Site Neoplasms Prostatic Diseases Dexamethasone Prednisone Docetaxel Pembrolizumab Anti-Inflammatory Agents Antiemetics Autonomic Agents |
Peripheral Nervous System Agents Physiological Effects of Drugs Gastrointestinal Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Antineoplastic Agents, Hormonal Antineoplastic Agents Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action Antineoplastic Agents, Immunological |